A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients.

Project Information

MERCURIC

Grant agreement ID: 602901

Project closed

Start date 1 December 2013

End date 31 December 2019

Funded under

• Specific Programme "Cooperation": Health

Total cost

€ 4 552 218,68

EU contribution

€ 3 458 520,48

Coordinated by

THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom

• Trialling tailored treatments for colorectal cancer
  EN